E2F1 and metabolic dysfunction-associated steatotic liver disease: Subsequently, ALT and AST levels in the serum of NAFLD mice were reduced by treatment with EVs-inhibitor-NC + LV-sh-NC but rescued in response to EVs-miR-223-3p inhibitor, whereas additional E2F1 silencing further reduced ALT and AST levels (Figure 7c).